DNA encoding variant CD44 surface proteins associated with metastatic tumors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 9, 1996
Grant Date -
N/A
app pub date -
Nov 9, 1992
filing date -
May 7, 1990
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The presence of certain extracellular regions ('ECR') from human and rat variants of the CD44 membrane glycoprotein have been found to be associated with metastasis ability in tumor cells. Isolated polynucleotides encoding the ECRs permit expression of the ECR polypeptide, which in turn can be used as an antigen to obtain monoclonal antibodies that recognize the ECR polypeptide. The anti-ECR monoclonal antibodies have the ability to prevent metastasis by tumor cells that would otherwise metastasize and spread.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully